Your browser doesn't support javascript.
Effectiveness of convalescent plasma in Indian patients with COVID-19.
Budhiraja, Sandeep; Dewan, Arun; Aggarwal, Ritesh; Singh, Omender; Juneja, Deven; Pathak, Sangeeta; Singh, Y P; Gupta, Ajay; Rai, Reeta; Indrayan, Abhaya; Jha, Vinitaa; Naithani, Rahul.
  • Budhiraja S; Clinical Directorate, Max Healthcare, New Delhi, India; Institute of Internal Medicine, Max Healthcare, New Delhi, India. Electronic address: sbudhiraja@maxhealthcare.com.
  • Dewan A; Critical Care, Max Healthcare, New Delhi, India. Electronic address: Arun.Dewan@maxhealthcare.com.
  • Aggarwal R; Critical Care, Max Healthcare, New Delhi, India. Electronic address: Ritesh.Aggarwal@maxhealthcare.com.
  • Singh O; Critical Care, Max Healthcare, New Delhi, India. Electronic address: Omender.Singh@maxhealthcare.com.
  • Juneja D; Critical Care, Max Healthcare, New Delhi, India. Electronic address: deven.juneja@maxhealthcare.com.
  • Pathak S; Transfusion Medicine, Max Healthcare, New Delhi, India. Electronic address: sangeeta.pathak@maxhealthcare.com.
  • Singh YP; Critical Care, Max Healthcare, New Delhi, India. Electronic address: Yogendra.Singh2@maxhealthcare.com.
  • Gupta A; Critical Care, Max Healthcare, New Delhi, India. Electronic address: DrAjay.Gupta@maxhealthcare.com.
  • Rai R; Transfusion Medicine, Max Healthcare, New Delhi, India. Electronic address: Reeta.Rai@maxhealthcare.com.
  • Indrayan A; Division of Bio Statistics, Max Healthcare, New Delhi, India.
  • Jha V; Clinical Directorate, Max Healthcare, New Delhi, India. Electronic address: Vinitaa.jha@maxhealthcare.com.
  • Naithani R; Hematology & Bone Marrow Transplant Division, Max Healthcare, New Delhi, India. Electronic address: Rahul.Naithani@maxhealthcare.com.
Blood Cells Mol Dis ; 88: 102548, 2021 05.
Article in English | MEDLINE | ID: covidwho-1086789
Semantic information from SemMedBD (by NLM)
1. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
2. Patients LOCATION_OF Convalescent plasma
Subject
Patients
Predicate
LOCATION_OF
Object
Convalescent plasma
3. COVID-19 PROCESS_OF hospitalized patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
hospitalized patients
4. treatment options PROCESS_OF hospitalized patients
Subject
treatment options
Predicate
PROCESS_OF
Object
hospitalized patients
5. Comorbidity PROCESS_OF Patients
Subject
Comorbidity
Predicate
PROCESS_OF
Object
Patients
6. Plasma LOCATION_OF AKR1A1 wt Allele
Subject
Plasma
Predicate
LOCATION_OF
Object
AKR1A1 wt Allele
7. COVID-19 PROCESS_OF geriatric patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
geriatric patients
8. geriatric patients LOCATION_OF Convalescent plasma
Subject
geriatric patients
Predicate
LOCATION_OF
Object
Convalescent plasma
9. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
10. Patients LOCATION_OF Convalescent plasma
Subject
Patients
Predicate
LOCATION_OF
Object
Convalescent plasma
11. COVID-19 PROCESS_OF hospitalized patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
hospitalized patients
12. treatment options PROCESS_OF hospitalized patients
Subject
treatment options
Predicate
PROCESS_OF
Object
hospitalized patients
13. Comorbidity PROCESS_OF Patients
Subject
Comorbidity
Predicate
PROCESS_OF
Object
Patients
14. Plasma LOCATION_OF AKR1A1 wt Allele
Subject
Plasma
Predicate
LOCATION_OF
Object
AKR1A1 wt Allele
15. COVID-19 PROCESS_OF geriatric patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
geriatric patients
16. geriatric patients LOCATION_OF Convalescent plasma
Subject
geriatric patients
Predicate
LOCATION_OF
Object
Convalescent plasma
ABSTRACT

BACKGROUND:

Convalescent plasma (CP) is being used as a treatment option in hospitalized patients with COVID-19. Till date, there is conflicting evidence on efficacy of CP in reducing COVID-19 related mortality.

OBJECTIVE:

To evaluate the effect of CP on 28-day mortality reduction in patients with COVID-19.

METHODS:

We did a multi-centre, retrospective case control observational study from 1st May 2020 to 31st August 2020. A total of 1079 adult patients with moderate and severe COVID-19 requiring oxygen, were reviewed. Of these, 694 patients were admitted to ICU. Out of these, 333 were given CP along with best supportive care and remaining 361 received best supportive care only.

RESULTS:

In the overall group of 1079 patients, mortality in plasma vs no plasma group was statistically not significant (22.4% vs 18.5%; p = 0.125; OR = 1.27, 95% CI 0.94--1.72). However, in patients with COVID-19 admitted to ICU, mortality was significantly lower in plasma group (25.5% vs 33.2%; p = 0.026; OR = 0.69, 95%CI 0.50-0.96). This benefit of reduced mortality was most seen in age group 60 to 74 years (26.7% vs 43.0%; p = 0.004; OR = 0.48, 95% CI 0.29-0.80), driven mostly by females of this age group (23.1% vs 53.5%; p = 0.013; OR = 0.26, 95% CI 0.09-0.78). Significant difference in mortality was observed in patients with one comorbidity (22.3% vs 36.5%; p = 0.004; OR = 0.50, 95% CI 0.31-0.80). Moreover, patients on ventilator had significantly lower mortality in the plasma arm (37.2% vs 49.3%; p = 0.009; OR = 0.61, 95% CI 0.42-0.89); particularly so for patients on invasive mechanical ventilation (63.9% vs 82.9%; p = 0.014; OR = 0.37, 95% CI 0.16-0.83).

CONCLUSION:

The use of CP was associated with reduced mortality in COVID-19 elderly patients admitted in ICU, above 60 years of age, particularly females, those with comorbidities and especially those who required some form of ventilation.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: Blood Cells Mol Dis Journal subject: Hematology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: Blood Cells Mol Dis Journal subject: Hematology Year: 2021 Document Type: Article